User menu

Rituximab given after high dose therapy and autologous stem cell transplantation induces durable clearance of minimal residual disease in about half of the patients with follicular non Hodgkin's lymphoma: 36 months results of a multicenter open label phase II trial (M39012 trial).

Bibliographic reference Morschhauser, F. ; Recher, C. ; Milpied, N. ; Gressin, R ; Salles, G. ; et. al. Rituximab given after high dose therapy and autologous stem cell transplantation induces durable clearance of minimal residual disease in about half of the patients with follicular non Hodgkin's lymphoma: 36 months results of a multicenter open label phase II trial (M39012 trial)..46th Annual Meeting of the American-Society-of-Hematology (San Diego(Ca), Dec 04-07, 2004). In: Blood, Vol. 104, no. 11, p. 214A (2004)
Permanent URL http://hdl.handle.net/2078.1/61128